DEC 2 0 2004

This facsimile message and its contents are legally privileged and confidential information intended solely for the use of the addressee. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution, copying or other use of this message and its contents is strictly prohibited. If you have received this telecopy in error, please notify us immediately by telephone and return the original message to us at the address shown below via the Postal Service. Thank You.

ALSTON&BIRD LLP

3201 Beechleaf Court, Suite 600 Raleigh, NC 27604-1062 919-862-2200 Fax: 919-862-2260

TELECOPY

PLEASE DELIVER AS SOON AS POSSIBLE

Date:			
December	20, 2004		
Recipient:		Сотрапу:	
Mail Stop AF		U.S. Patent & Trademark Office	
Fax Number:		Voice Number:	
703-872-9306		· · · · · · · · · · · · · · · · · · ·	
Sender:			
W. Muita	y Spruill		
Message:			
Please file the	attached Amendment After	Final Action in the followin	g application:
Appl. No.: Applicant(s): Filed: Art Unit: Examiner: Title:		3, 2001	
	Num	ber of Pages: (including co	over page) 8
IF NOT REC	EIVED PROPERLY, PLEA	ASE NOTIFY US IMMEDIA	TELY AT Karyn Grimm.
USER CODE:	SPRUM	REQUESTED BY:	Karyn Grimm
CLIENT/MATTER: 035721/239475 OPERATOR:			

RECEIVED CENTRA! FAX CENTER

DEC 2 0 2014

PATENT

RESPONSE UNDER 37 C.F.R. 1.116 - EXPEDITED PROCEDURE - EXAMINING GROUP 1653

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No.:

10/007,716

Confirmation No.: 6335

Applicant(s):

Yun-Hwa Peggy Hsich November 13, 2001

Filed: Art Unit:

1653

Examiner:

Abdel A. Mohamed

Title:

USE OF JELLYFISH COLLAGEN (TYPE II) IN

THE TREATMENT OF RHEUMATOID ARTHRITIS

Docket No.:

35721/239475(5721-17)

Customer No.: 00826

Mail Stop AF Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

AMENDMENT AFTER FINAL ACTION **PURSUANT TO 37 C.F.R. § 1.116**

Sir:

In response to the Final Office Action dated October 20, 2004, please amend the aboveidentified application as follows:

Amendments to the Claims are reflected in the listing of claims beginning on page 2 of this paper.

Remarks begin on page 5 of this paper.